Abstract:161 Objectives: T cell infiltration of tumor lesions is a known prognostic factor in several tumor types and is used as treatment mechanism in some of these tumor types. Tumor infiltrating T cells express the high affinity interleukin-2 (IL2) receptor (CD25) on their surface. These T cells could therefore be visualized by molecular imaging with a radiolabeled IL2 for this receptor. For this purpose, [18F]FB-IL2 was designed as a PET imaging probe for T cell imaging, but strictly limited by its low target-to-background ratios and toxicity, which was resulted from direct binding of IL-2 to αβγ IL-2Rs on lung endothelial cells. Interaction of IL-2 with lung endothelial cells can be abrogated by blocking IL2 and IL-2Rα interaction. Here we developed a novel T cell imaging probe based on mutant Interleukin-2 (mIL2), which reduced binding to IL-2Rα and increased binding affinity for IL-2Rβ and may lead to higher target-to-background ratios and less toxicity in vivo than IL2. Methods: Mutant Interleukin-2 was expressed in Sf9 cells and purified by Ni-NTA, then concentrated using spin concentrators and purified with an FPLC Superdex 75 sizing column. The bioactivity of purified mIL2 was detected with the CTLL2 cells which were dependent upon IL-2 for growth. IL2/IL-2Rα interaction was detected by ELISA. Then, mIL2 was radiolabeled with 99mTc-HYNIC-GGGGK conjugated to the LPETG tag through Sortase A. The pharmacokinetic data of 99mTc-HYNIC-mIL2 was obtained by ex vivo biodistribution experiments. Finally, the tumor infiltrating T cells detecting capability of 99mTc-HYNIC-mIL2 in MC38 subcutaneous tumor-bearing mice was evaluated by in vivo NanoScan SPECT/CT imaging. Results: mIL2 showed bioactivity with CTLL2 cells whereas lower CD25 binding compared with IL2. The 99mTc-labeling procedure was done within 2 h, with a yield of 70%. The radiochemical purity was greater than 98%. As shown in figure 1, the tumor-infiltrating T cells located in the MC38 tumor margin was clearly visualized by 99mTc-HYNIC-mIL2 NanoScan SPECT/CT imaging with low background except relatively high kidney uptake at all detected time points (0.5 and 2 h p.i.). Specificity of 99mTc-HYNIC-mIL2 to T cells was demonstrated by competitive blocking of tumor uptake with excess mIL2. Biodistribution results showed that the tumor uptake of 99mTc-HYNIC-mIL2 at 0.5 and 2 h p.i. was 2.59 ± 0.37 %ID/g and 2.19 ± 0.16 %ID/g, respectively. Conclusions: 99mTc-HYNIC-mIL2 is a promising SPECT radiotracer for the noninvasive imaging of tumor infiltrating T cells, which showed high target-to-background ratios. This novel tracer possesses enormous potential for evaluating and guiding immunotherapy in clinical practice, and its further investigation is still in progress.

Animal SPECT/CT imaging and radiation dosimetry of~(99m)Tc-HYNIC-TOC

Somatostatin receptor subtype 2-mediated scintigraphy and localization using 99mTc-HYNIC-Tyr3-octreotide in human hepatocellular carcinoma-bearing nude mice

(99M)tc-Labeled Dimeric Octreotide Peptide: a Radiotracer with High Tumor Uptake for Single-Photon Emission Computed Tomography Imaging of Somatostatin Receptor Subtype 2-Positive Tumors.

Small-Animal Spect/Ct Imaging with 99Mtc-Hynic-h10f Detects Her2 Expression in Mice Bearing Human Breast Cancers

Evaluation of 99Mtc-Hydrazinonicotinamide-tyr3-octreotide SPECT/CT in Detection of Liver Metastases in Patients with Neuroendocrine Tumors

Anti-carcinoma Effect of Targeted Radiotherapy Using 90Y-Dota-octreotide Mediated by Somatostatin Receptor

Dosimetry estimation and preliminary clinical application of [99mTc]Tc-HYNIC-PSMA-XL-2 in prostate cancer

Study of Distribution and Antisense Imaging for 99Mtc-Ason-egf in Breast Cancer-Bearing Nude Mouse Models

The Study on Tumor Cell Apoptotic Imaging in Vivo with ~99Tc~m-Hynic-annexin V in Mice Tumorbearing

Experimental Study on Roles of 99Mtc-Hl91 Imaging and Carbogen Breathing in 32P-Colloid Interstitial Treatment of Malignant Tumor

Preparation and Evaluation of Tc-99m-Labeled Dimeric Tyr(3)-Octreotide in the Ar42j Tumor Model

<sup>99m</sup>Tc-Labeled Bombesin(7−14)NH<sub>2</sub>with Favorable Properties for SPECT Imaging of Colon Cancer

The Study on Tumor Cell Apoptotic Imaging in Vivo with 99Tcm-Hynic-annexin V in Mice Tumor-Bearing

Tc-99m-Labeled Bombesin(7-14)Nh2 With Favorable Properties For Spect Imaging Of Colon Cancer

An Experimental Study on Mice Bearing Liver Cancer Imaging with ~(99)Tc~m-Hl91

SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99Mtc-Hynic-h6f in Breast Cancer Mouse Models.

Biodistribution of ~(131)I-D_2C_5 in nude mice bearing tumor

99Tcmn-Dgdtc,a New Glucose Metabolic Agent,the Pharmacokinetics and Imaging Results

99Mtc-Labeled Mutant Interleukin-2 As a Promising SPECT Probe for in Vivo Imaging of Tumor-Infiltrating T Cells

Clinical Application of 99Mtc-Hynic-toc SPECT/CT in Diagnosing and Monitoring of Pancreatic Neuroendocrine Neoplasms

Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer